PURPOSE: The current work assessed the independent contributions of age, comorbidities, tumor features, and treatment approach to the outcome of elderly patients with breast cancer. PATIENTS AND METHODS: Records of consecutive women aged > or = 70 years with a histologic diagnosis of first invasive breast cancer between 1971 and 2001 and available medical information were reviewed. Restaging to the 2002 TNM system and comorbidity data abstraction were performed. Primary outcomes were overall survival (OS) and breast cancer-specific survival (BCSS). RESULTS: There were 992 patients with a median diagnosis age of 76 years, of whom 840 were approached with a curative intent. Significant comorbidities were recorded as none and > or = 3 in 13% and 44% of patients, respectively. The 5- and 10-year OS rates were 59% and 34%; corresponding BCSS rates were 74% and 62%, respectively. Of 693 patients who died during the study period, only 298 (43%) died from their tumors. Stage emerged as the strongest predictor determining OS and BCSS (P = 0.001). In curatively approached patients, age was the next dominant factor affecting survival length (P = 0.001). The comorbidities with significant effect on OS differed by stage and included heart failure, diabetes, and other common comorbidities in early tumors but only extremely debilitating ones in advanced-stage disease (P < 0.05). Significant favorable effect of systemic therapy emerged only in the univariate model. CONCLUSION: This study confirms tumor stage as the strongest predictor of survival in elderly patients with breast cancer. It also indicates a significant role for age and comorbidities that varies by stage. Treatment effect should be interpreted with caution because of the retrospective study nature.
PURPOSE: The current work assessed the independent contributions of age, comorbidities, tumor features, and treatment approach to the outcome of elderly patients with breast cancer. PATIENTS AND METHODS: Records of consecutive women aged > or = 70 years with a histologic diagnosis of first invasive breast cancer between 1971 and 2001 and available medical information were reviewed. Restaging to the 2002 TNM system and comorbidity data abstraction were performed. Primary outcomes were overall survival (OS) and breast cancer-specific survival (BCSS). RESULTS: There were 992 patients with a median diagnosis age of 76 years, of whom 840 were approached with a curative intent. Significant comorbidities were recorded as none and > or = 3 in 13% and 44% of patients, respectively. The 5- and 10-year OS rates were 59% and 34%; corresponding BCSS rates were 74% and 62%, respectively. Of 693 patients who died during the study period, only 298 (43%) died from their tumors. Stage emerged as the strongest predictor determining OS and BCSS (P = 0.001). In curatively approached patients, age was the next dominant factor affecting survival length (P = 0.001). The comorbidities with significant effect on OS differed by stage and included heart failure, diabetes, and other common comorbidities in early tumors but only extremely debilitating ones in advanced-stage disease (P < 0.05). Significant favorable effect of systemic therapy emerged only in the univariate model. CONCLUSION: This study confirms tumor stage as the strongest predictor of survival in elderly patients with breast cancer. It also indicates a significant role for age and comorbidities that varies by stage. Treatment effect should be interpreted with caution because of the retrospective study nature.
Authors: Rachel M Gonzalez; Don S Daly; Ruimin Tan; Jeffrey R Marks; Richard C Zangar Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-05-17 Impact factor: 4.254
Authors: Gretchen Kimmick; Steven T Fleming; Susan A Sabatino; Xiao-Cheng Wu; Wenke Hwang; J Frank Wilson; Mary Jo Lund; Rosemary Cress; Roger T Anderson Journal: J Am Geriatr Soc Date: 2014-02-10 Impact factor: 5.562
Authors: Heidi D Klepin; Brandelyn N Pitcher; Karla V Ballman; Alice B Kornblith; Arti Hurria; Eric P Winer; Clifford Hudis; Harvey J Cohen; Hyman B Muss; Gretchen G Kimmick Journal: J Oncol Pract Date: 2014-07-29 Impact factor: 3.840
Authors: Isabelle Soerjomataram; Marieke W J Louwman; Jacques G Ribot; Jan A Roukema; Jan Willem W Coebergh Journal: Breast Cancer Res Treat Date: 2007-03-22 Impact factor: 4.872